Updated on October 20, 2026
HGH follow-up means regular check-ins and blood tests while you are on growth hormone therapy. Under the Endocrine Society guideline, you are checked every 1 to 2 months while your dose is being adjusted, then every 6 months once it is stable. Each check looks at your IGF-1 level, any side effects, and how you feel. Fasting glucose and a lipid panel are added once a year.
This guide covers each test, the schedule, and what usually leads to a dose change. For a deeper look at the main marker, see our IGF-1 monitoring guide.
Why does HGH therapy need regular follow-up?
Because the right dose is different for every person, and the only way to find it is to measure. The guideline recommends starting low and adjusting by symptoms, side effects and IGF-1 levels, not by body weight.
Natural growth hormone output falls with age. In one study of healthy men, each decade of age cut daily GH production by about 14%. Replacing it is not a one-time fix. Too little does nothing for you, and too much brings side effects. Follow-up keeps you between the two.
Dose needs also differ between men and women. Women who take oral estrogen usually need a higher dose to reach the same IGF-1 level, because oral estrogen reduces how much IGF-1 the liver makes.
How often should you be checked on HGH?
Every 1 to 2 months while your dose is being adjusted, then every 6 months once it is stable.
| Stage | When | What is checked |
|---|---|---|
| Before you start | Baseline | Full blood panel (see HGH blood test) |
| Finding your dose | Every 1 to 2 months | IGF-1, side effects, how you feel |
| Stable dose | Every 6 months | IGF-1, side effects, clinical check |
| Yearly | Every 12 months | Fasting glucose, lipid panel |
| Low bone density at baseline | Every 1.5 to 2 years | DXA bone scan |
Dose changes are made in small steps. The guideline describes raising the daily dose by 0.1 to 0.2 mg every 1 to 2 months until your IGF-1 and symptoms are where they should be. Read more about HGH dosage.
Which tests are part of HGH follow-up?
IGF-1 is the main one. Glucose, lipids, thyroid and, for some patients, cortisol and bone density complete the picture.
IGF-1
Growth hormone tells the liver to make IGF-1, so your IGF-1 level shows how strongly your dose is working. The goal is a level inside the normal range for your age. Many doctors aim for the upper half of that range, although the guideline notes that no study has set an exact target.
Fasting glucose
Growth hormone can lower insulin sensitivity, mostly at higher doses. Fasting glucose is checked once a year. If you have diabetes, it is checked more often, and your diabetes medication may need adjusting.
Lipid panel
Cholesterol and triglycerides are checked once a year to track heart and metabolic health.
Thyroid and cortisol
HGH can lower free T4 and cortisol levels. In people with pituitary conditions, this can reveal a thyroid or adrenal problem that was hidden before treatment. If you already take thyroid medication, your dose may need adjusting after you start HGH.
Bone density and body measurements
If your first DXA scan showed low bone density, it is repeated every 1.5 to 2 years. Do not judge it too early. Bone density can stay flat or even dip in the first 12 months; most studies then show gains of 4 to 10% after 18 to 24 months. Waist measurement and quality-of-life questionnaires are simple extra ways to track progress.
What side effects should you report between visits?
Swelling, joint pain, muscle aches, and tingling or numbness in the hands. These come from fluid retention and are the most common side effects.
They affect roughly 5 to 18% of adult patients, and carpal tunnel syndrome about 2%. Older, heavier and female patients are more prone to them. Most improve when the dose is lowered, so report them right away instead of waiting for your next check. See the full list of HGH side effects.
Growth hormone is not used when there is an active cancer. Tell your doctor about any new diagnosis immediately.
How does follow-up work with HGH Vallarta?
You do not need to fly back to Puerto Vallarta for each check. Blood tests are done at a lab near you, and our doctors review the results and adjust your dose.
Your medication is delivered with a cooler, and you are welcome to visit the clinic if you prefer to pick it up in person. Prescriptions are written by our licensed doctors, Dr. Roberto Gutierrez Meza and Dr. Adrian Eduardo Cuenca Bravo, and filled by licensed Mexican pharmacies. Learn how the HGH prescription process works.
HGH follow-up FAQ
How soon after starting HGH is the first follow-up?
Usually 1 to 2 months after your first dose. That check shows how your IGF-1 has responded to the starting dose and whether you have side effects. Based on it, your doctor keeps, raises or lowers the dose. The check is then repeated every 1 to 2 months until the dose is stable.
Do I still need blood tests once my dose is stable?
Yes. Once your dose is stable, the guideline recommends a check every 6 months with an IGF-1 test, plus fasting glucose and a lipid panel once a year. IGF-1 can shift with weight, age and other medicines, so a dose that was right last year may not be right today.
What IGF-1 level is the goal on HGH?
A level within the normal range for your age. Many doctors aim for the upper half of that range. A result above the range usually means the dose is too high, even if you feel fine. A result below it with no improvement in symptoms may mean the dose is too low.
Can I do my HGH follow-up tests where I live?
Yes. HGH Vallarta patients do their blood tests at a lab near home and send the results to our doctors for review. Your dose is adjusted from those results, and your medication is delivered to you. You only travel to the clinic if you want to.
Sources
- Molitch ME, Clemmons DR, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. https://doi.org/10.1210/jc.2011-0179
- Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991;73(5):1081-1088. https://doi.org/10.1210/jcem-73-5-1081
